Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model.

abstract：:Rituximab, an anti CD20 monoclonal antibody, has now become a cornerstone in the treatment of many CD20 positive hematological malignancies and a variety of autoimmune disorders. In contrast to the acute allergic and cytokine associated reactions, late adverse events of rituximab are indeed uncommon but at the same ti...

journal_title：Leukemia & lymphoma

authors： Ram R,Ben-Bassat I,Shpilberg O,Polliack A,Raanani P

更新日期：2009-07-01 00:00:00

abstract：:Much progress has been made in the field of allogeneic stem cell transplantation. However, one major barrier is the delay in immune recovery that can persist for months post-transplant and results in increased susceptibility to infection and relapse of malignancy. Strategies to improve immune recovery must be balanced...

journal_title：Leukemia & lymphoma

authors： Snyder KM,Mackall CL,Fry TJ

更新日期：2006-07-01 00:00:00

abstract：:Primary myelosarcomas, also called leukemia cutis, granulocytic sarcomas or chloromas, are rare extramedullary manifestations of acute myeloid leukemia (AML) which precede bone marrow involvement. Skin infiltration was the most frequent localization associated with a myelomonocytic differentiation. Although first remi...

journal_title：Leukemia & lymphoma

authors： Reinhardt D,Creutzig U

更新日期：2002-03-01 00:00:00

abstract：:Baseline anemia is a relevant prognostic factor in the overall population of non-Hodgkin's lymphoma (NHL) patients, and studies focusing on elderly NHL are awaited. We conducted a pooled analysis of a cohort of comparable patients enrolled (1993 - 2001) in three multicenter clinical trials on use of a MACOP-B-like reg...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Tani M,Alinari L,Molinari AL,Stefoni V,Visani G,Gentilini P,Guardigni L,Fina M,Baccarani M

更新日期：2005-10-01 00:00:00

abstract：:Aggressive B-cell non-Hodgkin lymphoma (aNHL) accounts for ∼50% of all NHL cases. The only potentially curative, broadly available treatment for patients with relapse, failing frontline treatment, is high-dose therapy followed by autologous stem cell transplantation (ASCT); patients ineligible for/who have failed ASCT...

journal_title：Leukemia & lymphoma

authors： Salles GA,Pettengell R,Cordoba R,Długosz-Danecka M,Jurczak W,Tilly H

更新日期：2019-07-01 00:00:00

abstract：:P53 protein expression in malignant cells of five patients with Burkitt lymphoma (BL) and from two patients with B-cell acute lymphoblastic leukemia (B-ALL) was examined with anti p53 protein monoclonal antibodies PAb1801, PAb240 and p53-D07 using an immunocytochemical technique. Four of the seven patients were positi...

journal_title：Leukemia & lymphoma

authors： Nagai J,Kigasawa H,Koga N,Katoh A,Nishihira H,Nagao T

更新日期：1998-02-01 00:00:00

abstract：:The etiology of chronic lymphocytic leukemia (CLL) appears to be influenced by genetic factors which may contribute to its differential, gender- and age-specific incidence. The presented study is the first, which investigated the frequencies of DNA-typed alleles of all relevant human leukocyte antigens (HLA) loci in C...

journal_title：Leukemia & lymphoma

authors： Mueller LP,Machulla HK

更新日期：2002-05-01 00:00:00

abstract：:A leukemia-associated CD9 glycoprotein antigen released into the extracellular milieu from acute lymphoblastic leukemia cells has been detected using a unique lectin-monoclonal antibody immunoassay. It has been demonstrated that the release of CD9 antigen is an active process and is associated with active cell growth....

journal_title：Leukemia & lymphoma

authors： Komada Y,Sakurai M

更新日期：1994-02-01 00:00:00

abstract：:The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

journal_title：Leukemia & lymphoma

authors： Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

更新日期：2019-01-01 00:00:00

abstract：:Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetyla...

journal_title：Leukemia & lymphoma

authors： Duvic M,Bates SE,Piekarz R,Eisch R,Kim YH,Lerner A,Robak T,Samtsov A,Becker JC,McCulloch W,Waksman J,Whittaker S

更新日期：2018-04-01 00:00:00

abstract：:Herbal remedies are clearly a complementary and alternative modality used frequently by patients with hemato-oncological neoplasias during the course of their specific treatment. This review focuses on the potential safety and efficacy of herbs which are either used often or even on a daily basis by patients with hema...

journal_title：Leukemia & lymphoma

authors： Ben-Arye E,Attias S,Tadmor T,Schiff E

更新日期：2010-08-01 00:00:00

abstract：:Multiple myeloma (MM) is an essentially incurable malignancy associated with profound immune dysregulation. Despite the advent of novel therapies and improvements in survival over the last 10 years, death from progressive disease and infection remains a common outcome. Natural killer (NK) cells are CD56(+)CD3(-) large...

journal_title：Leukemia & lymphoma

authors： Godfrey J,Benson DM Jr

更新日期：2012-09-01 00:00:00

abstract：:We have evaluated the severe combined immunodeficient (SCID) mouse as an in-vivo model for the study of non-Hodgkin's lymphomas (NHL). Characterization of the immune system of the animals in our SCID mouse colony was carried out to assess the numbers of lymphoid cells present, to determine natural killer (NK) cell act...

journal_title：Leukemia & lymphoma

authors： Zubair AC,Ali SA,Rees RC,Goepel JR,Winfield DA,Goyns MH

更新日期：1996-08-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evi...

journal_title：Leukemia & lymphoma

authors： Gadhoum Z,Delaunay J,Maquarre E,Durand L,Lancereaux V,Qi J,Robert-Lezenes J,Chomienne C,Smadja-Joffe F

更新日期：2004-08-01 00:00:00

abstract：:Graft-versus-host disease (GVHD) represents the major barrier to successful allogeneic bone marrow transplantation. Positive and negative selection studies have unequivocally demonstrated that donor T cells are responsible for the induction phase of GVHD. Inhibition of the early steps of T cell antigen recognition lea...

journal_title：Leukemia & lymphoma

authors： Schlegel PG,Chao NJ

更新日期：1996-09-01 00:00:00

abstract：:B-cell chronic lymphocytic leukemia (CLL) is characterized by profound immune dysfunction and a marked resistance to apoptosis. Understanding the cellular biology of immune effector cells from CLL patients as well as leukemic target cells is essential to developing immune mediated therapeutic strategies for CLL. In th...

journal_title：Leukemia & lymphoma

authors： Vu UE,Pavletic ZS,Wang X,Joshi SS

更新日期：2000-11-01 00:00:00

abstract：:Primary breast lymphoma (PBL) is a rare form of localized extranodal lymphoma. Few reports are available in the literature concerning its treatment and outcome. Of the 34 cases of PBL seen at our institution over a 25-year period, 20 consecutive cases were treated with CHOP or CHOP-like chemotherapy regimen and had ad...

journal_title：Leukemia & lymphoma

authors： Gholam D,Bibeau F,El Weshi A,Bosq J,Ribrag V

更新日期：2003-07-01 00:00:00

abstract：:We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 ...

journal_title：Leukemia & lymphoma

authors： Crocchiolo R,Canevari C,Assanelli A,Lunghi F,Tassara M,Stanghellini ML,Clerici D,Landoni C,Servida P,Bernardi M,Peccatori J,Ferreri A,Gianolli L,Bordignon C,Caligaris-Cappio F,Ciceri F,Fazio F

更新日期：2008-04-01 00:00:00

abstract：:The standard CHOP regimen may cure 30-40% of patients with advanced aggressive non-Hodgkin's lymphoma (ANHL). Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity. This study was designed to com...

journal_title：Leukemia & lymphoma

authors： Pangalis GA,Vassilakopoulos TP,Michalis E,Roussou P,Vrakidou E,Repousis P,Angelopoulou MK,Siakantaris MP,Korantzis J,Symeonidis A,Grigorakis V,Stefanoudakis E,Stamatellou M,Bourantas KL,Kalmantis T,Christopoulos G,Kokkini

更新日期：2003-04-01 00:00:00

abstract：:Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates o...

journal_title：Leukemia & lymphoma

authors： Cummins KD,Gill S

更新日期：2018-07-01 00:00:00

abstract：:In this report, we present a patient with chronic myeloid leukemia (CML) in blastic phase who had two consecutive episodes of spontaneous regression back to chronic phase without chemotherapy. Although, spontaneous remission (SR) is well documented in acute leukemia, SR in CML blastic phase is extremely rare and to th...

journal_title：Leukemia & lymphoma

authors： Cağirgan S,Sencan M,Tombuloglu M,Ozdemir E,Hekimgil M,Büyükkeçeci F

更新日期：1998-04-01 00:00:00

abstract：:Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-a...

journal_title：Leukemia & lymphoma

authors： Lim MY,Al-Kali A,Ashrani AA,Begna KH,Elliott MA,Hogan WJ,Hook CC,Kaufmann SH,Letendre L,Litzow MR,Patnaik MS,Pardanani A,Tefferi A,Wolanskyj AP,Grill DE,Pruthi RK

更新日期：2013-06-01 00:00:00

abstract：:Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). We conducted a retrospective study of adult patients with DLBCL initially treated with rituximab containin...

journal_title：Leukemia & lymphoma

authors： Carella AM,de Souza CA,Luminari S,Marcheselli L,Chiappella A,di Rocco A,Cesaretti M,Rossi A,Rigacci L,Gaidano G,Merli F,Spina M,Stelitano C,Hohaus S,Barbui A,Puccini B,Miranda EC,Guida A,Federico M

更新日期：2013-01-01 00:00:00

abstract：:Rapamycin and its derivatives have been proposed in the treatment of leukemia based on their cytostatic effects, but their possible role in differentiation therapy is less explored. The aim of the present study was to investigate the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide (D...

journal_title：Leukemia & lymphoma

authors： Lalic H,Lukinovic-Skudar V,Banfic H,Visnjic D

更新日期：2012-11-01 00:00:00

abstract：:Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inh...

journal_title：Leukemia & lymphoma

authors： Walker JS,Garzon R,Lapalombella R

更新日期：2020-10-01 00:00:00

abstract：:The emergence of radioimmunotherapy (RIT) provides a new therapeutic approach in which monoclonal antibodies directed against tumor-specific antigens are used to target therapeutic radioisotopes to sites of disseminated disease. The target cell is eliminated and adjacent tumor cells, to which antibody has not bound, a...

journal_title：Leukemia & lymphoma

authors： Bischof Delaloye A

更新日期：2003-01-01 00:00:00

abstract：:The expression of the interleukin 2 (IL2) receptor chains was investigated by immunofluorescence and mRNA analysis in typical and variant hairy cell leukemia (HCL) cases. While typical hairy cells express both the alpha and the beta chains, variant HCL express the IL2 receptor beta chain on the surface membrane but no...

journal_title：Leukemia & lymphoma

authors： de Totero D,Carbone A,Tazzari PL,Raspadori D,Ventura A,Reato G,Lauria F,Foa R

更新日期：1994-01-01 00:00:00

abstract：:Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunological...

journal_title：Leukemia & lymphoma

authors： Gergis U,van Besien K

更新日期：2019-09-01 00:00:00

abstract：:Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by study. Sixty-nine cases of diffuse large B-cell lymphoma were evalua...

journal_title：Leukemia & lymphoma

authors： Clark Schneider KM,Banks PM,Collie AM,Lanigan CP,Manilich E,Durkin LM,Hill BT,Hsi ED

更新日期：2016-07-01 00:00:00

abstract：:Current understanding of molecular genetics enables the establishment of new categories based on pathogenesis. Philadelphia (Ph) chromosome-positive leukemia has been reclassified into two molecularly distinct subsets, and the leukemogenesis at the cell level might be linked to the molecular changes. Therefore, treatm...

journal_title：Leukemia & lymphoma

authors： Ohyashiki K,Ohyashiki JH,Toyama K

更新日期：1993-01-01 00:00:00